Search results: (10000)
News Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
New molecules in hemophilia therapy have raised many questions, including regarding the significance and need for immune tolerance induction (ITI). Interesting conclusions from the FIT (Future of Immunotolerance Treatment) expert panel discussion on the future of ITI, its form, and indication were published in July 2019.
News Population Pharmacokinetics of Perioperative Administration of Coagulation Factors in Patients with von Willebrand Disease
For many patients with von Willebrand disease, the administration of coagulation factors is an important part of perioperative care. Due to the absence of pharmacokinetic models, predicting therapeutic levels is challenging, leading to a higher risk of bleeding or thrombotic events. To create the missing model, a long-term study was conducted by Dutch authors.
News INTERACTIVE CASE STUDY of a patient with mCRC treated long-term with various modalities
MUDr. Stanislav John, Ph.D.,
Clinic of Oncology and Radiotherapy, Faculty of Medicine, Charles University and University Hospital Hradec Králové
News Can the Treatment of Hypertension Prevent Recurrence of Atrial Fibrillation?
Atrial fibrillation (Afib) is the most common serious heart rhythm disorder and is responsible for a significant portion of deaths in the population. Hypertension is the most common and potentially modifiable risk factor for Afib. A newly published meta-analysis compares the effect of angiotensin receptor antagonism and calcium channel blockade on Afib recurrence in patients with hypertension and Afib.
News Virtual Echocardiography as a Potential Screening Tool for the Diagnosis of Primary Pulmonary Hypertension
Primary pulmonary hypertension disease is associated with a poor prognosis. Early diagnosis and the implementation of specific therapy are necessary to improve patients' prospects. In the near future, virtual echocardiography, which has shown good results in published studies, may become a valuable screening tool.
News Tool for Predicting Cardiometabolic Risk in Young Patients with Psychotic Disorder
A study describing the development and validation of an algorithm for predicting cardiometabolic risk in patients with psychotic disorder, PsyMetRiC (Psychosis Metabolic Risk Calculator), was recently published in Lancet Psychiatry. British scientists have created a tool to estimate the risk of developing metabolic syndrome over the next 6 years, serving as a predictor of cardiovascular morbidity and mortality in young people with psychosis aged 16–35 years.
News COVID-19 and MS: Do You Know the Risk Factors? What the American Registry Analysis Showed
An article published in the March issue of the prestigious journal JAMA Neurology summarizes the findings of an analysis of the course of COVID-19 in patients with multiple sclerosis in North America. Which patients are at greater risk of severe infection?
News Benefit of Adding Erdosteine to Maintenance Treatment of COPD
Erdosteine is a mucoactive drug with anti-inflammatory, antioxidant, and anti-adhesive effects against bacteria, commonly used in the treatment of chronic obstructive pulmonary disease (COPD). In August 2022, another post-hoc analysis of the RESTORE study was published, evaluating the impact of its addition to COPD maintenance treatment on the incidence and severity of exacerbations and quality of life in patients with GOLD2 and GOLD3 grade bronchial obstruction.
News How to Improve Diabetic Adherence?
The dream of every doctor is a conscientious patient who follows the prescribed treatment and reports any potential problems in a timely manner. But where can such a patient be found?
News In decisions about therapeutic strategy in multiple myeloma, patient preferences and concerns also play a crucial role
The perspective on the preferences of patients with multiple myeloma (MM) is very necessary at a time of rapid development of new treatment options. Patient priorities and their perception of treatment can, alongside the assessment of the efficacy or toxicity of a modality, also influence decisions about the therapeutic strategy.
News Does Intense Monitoring After Colorectal Cancer Resection Bring Benefits?
Is it necessary to intensely monitor patients with colorectal cancer after curative resection? Not always, as shown by the results of the PRODIGE 13 study presented at the virtual ESMO 2020 conference.
News Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients
Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis strategies have been studied in morbidly obese patients; a recently published study compared the efficacy and safety of high doses of enoxaparin and unfractionated heparin.
News Pharmacokinetics of Concentrates for the Treatment of von Willebrand’s Disease
Von Willebrand's disease (vWD) is characterized by a deficiency or reduced functional capacity of von Willebrand factor (vWF) and, in more severe cases, by a deficiency of coagulation factor VIII (FVIII). Treatment usually requires repeated infusions of vWF and FVIII concentrate, with available products having different factor ratios. Repeated infusions of concentrates can lead to different FVIII exposures when using different products. The pharmacokinetics of two products with varying vWF and FVIII ratios have been compared in experimental preclinical and clinical studies.
News How do body weight and metabolic parameters change in patients first hospitalized for psychosis?
The most common cause of death in patients with schizophrenia is cardiovascular disease, which is closely related to obesity or metabolic syndrome. The study presented below examined changes in body weight and metabolic parameters during the first hospitalization of these patients.
News Patient Evaluation of Durvalumab Treatment Results
The interim analysis results of the PACIFIC study, which monitored the efficacy of durvalumab in the treatment of locally advanced unresectable non-small cell lung cancer (NSCLC), demonstrated a significantly longer progression-free survival (PFS) with this treatment compared to placebo. The following work analyzed one of the secondary objectives of the PACIFIC study − patient-reported outcomes (PRO).
News Safety of Dabigatran According to a Meta-Analysis of 7 Randomized Controlled Trials
Dabigatran is a direct thrombin inhibitor from the group of direct oral anticoagulants (DOACs), developed as an alternative to vitamin K antagonists. The aim of the recently published meta-analysis was to compare the risk of bleeding, fatal adverse events, and mortality in patients treated with dabigatran and conventional therapy.
News Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice – Results of the STAR-RA Study
Recent results from the ORAL Surveillance clinical trial have raised concerns about the cardiovascular adverse effects of tofacitinib in patients with rheumatoid arthritis. A comprehensive analysis of real-world clinical practice data, involving nearly 13,000 patients, focused on the cardiovascular safety of tofacitinib for this indication.
News Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?
A study published this year aimed to assess how often the risk of VTE is assessed in routine clinical practice in internally ill patients, what proportion of patients are suitable for thromboprophylaxis, and how many actually receive this treatment.
News Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction
Previous studies have shown that the oral antidiabetic drug empagliflozin reduces the risk of death from cardiovascular causes or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetic and non-diabetic patients. The aim of the EMPEROR-Reduced clinical study was to supplement data on the effect of empagliflozin on the incidence of heart failure worsening events requiring hospitalization or outpatient treatment.
News Hemophilia and Intensive Physical Activity Are Not Mutually Exclusive − Case Report of a Top Athlete
Traditionally, many doctors have been reluctant to allow men with hemophilia to engage in more intense physical activity, mainly due to concerns about bleeding caused by overexertion or injury. Today's prophylactic modalities, however, allow for prevention to be set in such a way that the risk of bleeding is significantly reduced. Modern treatment thus brings hope for hemophiliacs to participate in some sports that were previously not recommended. In addition to effective prophylaxis, appropriate training activities, developed with the participation of a physiotherapist and sports doctor, are also crucial.
News When Size Matters or What Is Small Is Effective
The systemic effect of an orally administered drug can be expected, among other things, if it has suitable physicochemical properties. How can insufficient absorption or poor solubility be solved? We provide the answer below.
News No deficiency of essential fatty acids in home parenteral nutrition
A Dutch-British study, the results of which were published in the Journal of Parenteral and Enteral Nutrition, addressed the issue of potential deficiency of essential fatty acids in patients using home parenteral nutrition.
News Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is estimated that a 60-year-old patient with T2DM loses an average of 6–7 years of life compared to a person of the same age without T2DM. What impact does modern pharmacotherapy have on this adverse balance?
News Therapy Change from Adalimumab to Baricitinib in Patients with Rheumatoid Arthritis
The aim of the presented analysis of data from the RA-BEAM study was to evaluate the clinical response of patients who were switched to baricitinib during the study due to an inadequate response to adalimumab.